A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line treatment in patients with metastatic gastric cancer.

ABSTRACT:

Background

Currently, there is no recommended standard third-line chemotherapy for metastatic gastric cancer.

Objectives

In this study, we aimed to evaluate irinotecan's efficacy and safety in treating metastatic gastric cancer after the failure of first- and second-line chemotherapy.

Design

Prospective single-arm, two-center, phase II trial.

Methods

Patients were aged 18-70 years, with histologically confirmed gastric adenocarcinoma and an Eastern Cooperative Oncology Group performance status of 0-1, progressed during or within 3 months following the last administration of second-line chemotherapy and had no other severe hematologic, cardiac, pulmonary, hepatic, or renal functional abnormalities or immunodeficiency diseases. Eligible patients received 28-day c

SUBMITTER: Yu N 

PROVIDER: S-EPMC10903192 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature